Welcome to our dedicated page for Mushrooms news (Ticker: MSRM), a resource for investors and traders seeking the latest updates and insights on Mushrooms stock.
Mushrooms Inc. reports company developments tied to mushroom biotechnology, mycelium materials, health supplements, and healthcare-oriented product concepts. Recurring updates include MYCO Thread, nutrient-delivery textile applications, bacterial detection materials, and the company’s LONGEVITY and SPORT+ supplements.
Company news also covers patent-related technology disclosures, business development activity, shareholder voting matters, governance topics, capital-structure updates, material agreements, and operating and financial results.
Mushrooms Inc. (OTC: MSRM) reported successful early-stage validation of its mycelium-based infection-detection technology and completed beta testing of the MycoLab.ai research platform on March 24, 2026. The company validated a visible color-change sensing mechanism and is preparing expanded testing, third-party validation, and strategic funding options.
Management said these milestones prompted a reassessment of a previously contemplated transaction with SecurCapital and the companies are evaluating alternative structures while keeping collaboration options open.
Mushrooms, Inc. (OTC: MSRM) agreed to acquire SecurCapital Corp by an all-stock Share Exchange Agreement, creating a logistics and finance platform. Closing is anticipated in early March 2026, subject to customary conditions and regulatory approvals.
Based on unaudited interim data, SecurCapital portfolio companies generate approximately $10 million trailing twelve-month revenue. Post-closing, Stephen Russell will become CEO of Mushrooms, Inc., the company intends a rebrand to SecurCapital Corp, and legacy biotechnology assets will be separated from the public vehicle.
Mushrooms Inc. (OTC: MSRM) has announced a significant share buyback by one of its board directors, Donald Steinberg, who purchased 5 million shares. This transaction involved no loans or costs to the company and aims to prevent further dilution by allocating these shares for strategic initiatives. CEO Kimberly Carlson emphasized the director's purchase as a commitment to shareholder value and company growth. Additionally, Mushrooms Inc. is set to ship mycelium-based materials to Germany for the development of a bacterial detection bandage in late July or early August, highlighting their innovation in sustainable healthcare solutions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.